#DDDD #4Dpharma's MRx051 trial found "relative increases in cytotoxic cells, CD8+ T cells and other immune subsets associated with anti-tumour activity". A very good start to the long road to commercialisation.

Additionally, "Analysis finds significant expression changes in 98 genes as a result of treatment with MRx0518 monotherapy generally well-tolerated.". Need larger numbers which will come in P2/P3 trials to be sure, but the safety element is a big plus.

For the MRx0518 plus pembrolizumab part A P1/P2 trial, 5 of the 12 patients saw clinical benefit from the treatment. It is also well-tolerated in general; a very good start indeed and the core of what makes Live Biotherapeutics so interesting. Let's see what part B trials show.

This also shows why #DDDD's investment profile is so attractive. The risk is diversified across a number of relatively safe treatments, and if any one of them passes all the trials it could potentially be a multi-bagger. For example if one of their oncology treatments works,

This could easily be a multi bagger. This doesn't include what happens if MORE than one passes all the stages, along with #4dpharma's intellectual property portfolio. I am confident in US investors pricing this much more highly than their UK counterparts have.

Also worth noting more generally that it's not all about how effective the treatment is. Even if #DDDD's treatments are as effective as others BUT they have less severe side effects, they become the treatment of choice. This is where Live Biotherapeutics excels. #4dPharma